Site Search
Displaying results 311 - 320 of 573
Resource | Publications,
The Asia-Pacific region is facing a 'hidden epidemic' of HIV among adolescents. There were an estimated 50,000 new HIV infections among adolescents aged 15-19 in 2014, accounting for 15 per cent of new infections. There are now around 220,000 adolescents living with HIV in the region, with large cities like Bangkok, Hanoi and Jakarta hubs of new infections.
Although new HIV infections are falling overall, they are rising among adolescents from key populations, in particular young gay men and other men who have sex with men. The rise in new infections coincides with an increase in risky behaviour, such as multiple sexual partners and inconsistent condom use.
These findings come in a new report, 'Adolescents: Under the Radar in the Asia-Pacific AIDS Response', published today by the Asia-Pacific Inter-Agency Task Team on Young Key Populations, which includes UNICEF, UNAIDS and others.
Resource | Fact Sheets,
WHO recommends initiation of ART for all people living with HIV at any CD4 cell count Fixed dose combinations (FDCs) containing TDF/XTC/EFV remain the preferred first line regimen for adults, adolescents and older children For the first time, DTG and EFV400 have been included as alternative first line regimens for adults and adolescents. DRV/r is an alternative option as part of secondline regimens, along with LPV/r and ATV/r.
Resource | Publications,
Over the last two years, countries have made progress in scaling up access to HIV prevention, diagnosis, and treatment. However continued late diagnosis of HIV infection and the unacceptably high proportion of people living with HIV not linked to care result in a low proportion of PLHIV who achieve viral suppression.
National AIDS and STI programme managers met in Manila in 2015 to agree on concrete actions towards reaching the 90-90-90 targets and related prevention and stigma targets by 2020.
Resource | Publications,
This document is the sixth strategic plan for the Cambodian HIV/AIDS Education and Care (CHEC), representing its sixth cycle of positive intervention in the lives of people living with HIV and AIDS and their families. The CHEC programme currently consists of four projects: the Gender-Based Violence (GBV) Project, Out of School Youth Project, Home-Based Care Project and Nutrition project.
Due to the recent shift of funding support from donor countries, and due to the fact that the HIV/AIDS infection prevalence rate in Cambodia has been significantly reduced to 0.6% in 2015, this strategic plan reflects the shift to focus on ongoing life-time support for people living with HIV/AIDS.
For CHEC, the period 2016 to 2019 is an exciting time of growth, learning, embracing new challenges, and continuing to positively impact the lives of PLHIV. CHEC can indeed be an
Resource | Fact Sheets,
Adolescents face significant barriers accessing and remaining in HIV treatment and care services.
WHO guidelines in 2015 support initiation of antiretroviral therapy for all adolescents living with HIV. Adolescent friendly health services should be developed, including support for adherence and retention in care.
Resource | Fact Sheets,
Differentiated care for HIV requires delivery of different care packages for people based on their needs.
As more people start treatment it is important to maximise the quality of care and ensure efficient health services. Updated WHO Consolidated ARV Guidelines will be available in December 2015 and include recommendations to support appropriate quality care.
Resource | Publications,
Until recently, diagnosis and treatment of HCV was complex. Suitable tools for screening and diagnosis were lacking, and treatment was hampered by limited efficacy and severe side effects. New medicines for the treatment of HCV have revolutionized HCV treatment. Combinations of these new medicines, which are generally well-tolerated and effective, can cure HCV in 12 weeks. This offers a huge opportunity to address HCV, in particularly among HIV/HCV co-infected people, who are more vulnerable as they progress faster to serious disease than HCV mono-infected people.
Resource | Data Sheets,
This document provides Cohort analysis for patients who started ART in 2013 (12 months), Cohort analysis for patients who started ART in 2012 (24 months) and Cohort analysis for patients who started ART in 2009 (60 months).
Resource | Publications,
The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) Secretariat organize an annual meeting with pharmaceutical companies and stakeholders to discuss antiretroviral (ARV) drug demand forecasts for adults and children.
The March 2015 meeting went beyond the usual three-year forecast by including a model of new ARVs that will be needed up to 2024. For the first time this year, the meeting also included a discussion on hepatitis B and C medicines.
Resource | Guidelines,
This early-release guideline makes available two key recommendations that were developed during the revision process in 2015. First, antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Second, the use of daily oral pre-exposure prophylaxis (PrEP) is recommended as a prevention choice for people at substantial risk of HIV infection as part of combination prevention approaches. The first of these recommendations is based on evidence from clinical trials and observational studies released since 2013 showing that earlier use of ART results in better clinical outcomes for people living with HIV compared with delayed treatment. The second recommendation is based on clinical trial results confirming the efficacy of the ARV drug tenofovir for use as PrEP to prevent people from acquiring HIV in a wide variety of settings and populations.